Moderna Flu Vaccine Rejected: FDA Dispute & Internal Agency Concerns

The Food and Drug Administration’s (FDA) rejection of Moderna’s application for its mRNA-based flu vaccine continues to reverberate through the pharmaceutical industry, raising questions about the agency’s regulatory approach under Health Secretary Robert F. Kennedy Jr. And sparking concerns about innovation. The decision, announced on February 11, 2026, isn’t simply about one vaccine; it signals a potential shift in how the FDA evaluates novel therapies, particularly those utilizing the increasingly prominent mRNA technology.

At the heart of the dispute lies the design of Moderna’s clinical trial. The FDA contends that the comparator flu shot used in the trial – GSK’s Fluarix Quadrivalent – wasn’t the “best standard of care,” particularly for individuals aged 65 and older, for whom high-dose flu vaccines are recommended. Moderna, however, argues that the trial was conducted according to plans discussed and initially agreed upon with regulators. The company also pointed out that its trial design mirrored those used for decades in flu vaccine development.

This disagreement isn’t merely semantic. The choice of comparator vaccine significantly impacts a trial’s results. A less effective comparator can make a new vaccine appear more efficacious, while a more effective one raises the bar for demonstrating superiority. The FDA’s insistence on a higher standard, while seemingly focused on patient safety, has been interpreted by some as an attempt to deliberately disadvantage Moderna’s vaccine. A senior FDA official, speaking anonymously to Stat, suggested Moderna could resubmit with data excluding the 65+ cohort, potentially “showing some humility” and acknowledging the initial deviation from FDA guidance.

The situation is further complicated by internal tensions within the FDA. According to reporting in The New York Times and CIDRAP, Dr. Peter Marks, the director of the FDA’s Center for Biologics Evaluation and Research, has been issuing a series of unexpected rejection letters to pharmaceutical companies. Sources within the agency suggest that Dr. Marks is actively seeking opportunities to reject applications, a move that has prompted pushback from review staff concerned about potential legal challenges and the disruption of established regulatory practices. One FDA staffer reportedly expressed concern that these actions “break with the agency’s practices.”

The FDA’s actions have also drawn criticism from outside the agency. Virologist Angela Rasmussen, PhD, of the University of Saskatchewan, noted that Moderna’s trial design is “essentially the trial design that every single flu vaccine has used,” suggesting the FDA’s concerns are atypical. Stephen Hoge, MD, Moderna’s president, expressed “surprise and confusion” over the decision, particularly given the FDA’s earlier support for the study plan.

The rejection of Moderna’s application isn’t happening in a vacuum. It comes amidst broader anxieties about the FDA’s direction under Secretary Kennedy Jr., who has previously expressed skepticism about vaccines. While the FDA has publicly denied that its decision is politically motivated, the timing and unusual nature of the rejection have fueled speculation about a hardening stance towards mRNA vaccines. The agency’s defense of its decision as prioritizing patient safety rings hollow to some, given the agency’s previous approval of the trial design.

Beyond the immediate implications for Moderna, the FDA’s actions have broader consequences for the pharmaceutical industry. The unpredictability of the review process is creating uncertainty and potentially chilling investment in innovative vaccine development. The CIDRAP report highlights that Moderna is at least the ninth company to receive a surprise rejection from Dr. Marks and his team. This lack of consistency raises concerns about the agency’s commitment to fostering innovation and its ability to provide clear and predictable guidance to developers.

Adding to the internal turmoil, reports indicate that Dr. Marks’ management style has created a hostile work environment within the FDA. Stat reports that multiple complaints have been filed against him, alleging sexual harassment, retaliation against subordinates and verbally abusive behavior. These allegations, if substantiated, could further erode confidence in the agency’s leadership and its ability to make sound regulatory decisions.

The situation with Moderna’s flu vaccine underscores the complex interplay between scientific rigor, regulatory oversight, and political considerations. While the FDA has a legitimate responsibility to ensure the safety and efficacy of vaccines, its recent actions raise questions about whether it is applying a consistent and transparent standard. The agency’s refusal to review Moderna’s application, coupled with the internal controversies surrounding Dr. Marks, casts a shadow over the future of vaccine development and the FDA’s role in safeguarding public health. The question now is whether Moderna will attempt to address the FDA’s concerns and resubmit its application, or whether this marks the beginning of a more adversarial relationship between the agency and the companies it regulates.